These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 23771513)

  • 1. Death receptor 5 agonistic antibody PRO95780: preclinical pharmacokinetics and concentration-effect relationship support clinical dose and regimen selection.
    Xiang H; Reyes AE; Eppler S; Kelley S; Damico-Beyer LA
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):405-15. PubMed ID: 23771513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Onartuzumab (MetMAb): using nonclinical pharmacokinetic and concentration-effect data to support clinical development.
    Xiang H; Bender BC; Reyes AE; Merchant M; Jumbe NL; Romero M; Davancaze T; Nijem I; Mai E; Young J; Peterson A; Damico-Beyer LA
    Clin Cancer Res; 2013 Sep; 19(18):5068-78. PubMed ID: 23894056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical pharmacokinetics of MFGR1877A, a human monoclonal antibody to FGFR3, and prediction of its efficacious clinical dose for the treatment of t(4;14)-positive multiple myeloma.
    Kamath AV; Lu D; Gupta P; Jin D; Xin Y; Brady A; Stephan JP; Li H; Tien J; Qing J; Damico-Beyer LA
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):1071-8. PubMed ID: 22203368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft.
    Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Rose WC; Kramer RA; Wild R; Lee FY
    Cancer Chemother Pharmacol; 2005 Nov; 56(5):455-64. PubMed ID: 15947929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose.
    Kamath AV; Lu D; Gupta P; Jin D; Xiang H; Wong A; Leddy C; Crocker L; Schaefer G; Sliwkowski MX; Damico-Beyer LA
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):1063-9. PubMed ID: 22203367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical pharmacokinetics and safety of Sym004: a synergistic antibody mixture directed against epidermal growth factor receptor.
    Skartved NJ; Jacobsen HJ; Pedersen MW; Jensen PF; Sen JW; Jørgensen TK; Hey A; Kragh M
    Clin Cancer Res; 2011 Sep; 17(18):5962-72. PubMed ID: 21825041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-Clinical Pharmacokinetics, Prediction of Human Pharmacokinetics and First-in-Human Dose Selection for CNTO 5825, an Anti-Interleukin-13 Monoclonal Antibody.
    Nnane IP; Xu Z; Zhou H; Davis HM
    Basic Clin Pharmacol Toxicol; 2015 Oct; 117(4):219-25. PubMed ID: 25683750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose.
    de Vries Schultink AHM; Doornbos RP; Bakker ABH; Bol K; Throsby M; Geuijen C; Maussang D; Schellens JHM; Beijnen JH; Huitema ADR
    Invest New Drugs; 2018 Dec; 36(6):1006-1015. PubMed ID: 29728897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors.
    Doi T; Murakami H; Ohtsu A; Fuse N; Yoshino T; Yamamoto N; Boku N; Onozawa Y; Hsu CP; Gorski KS; Friberg G; Kawaguchi T; Sasaki T
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):733-41. PubMed ID: 21161528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety.
    Kelley SK; Harris LA; Xie D; Deforge L; Totpal K; Bussiere J; Fox JA
    J Pharmacol Exp Ther; 2001 Oct; 299(1):31-8. PubMed ID: 11561060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics/dynamics of 5c8, a monoclonal antibody to CD154 (CD40 ligand) suppression of an immune response in monkeys.
    Gobburu JV; Tenhoor C; Rogge MC; Frazier DE; Thomas D; Benjamin C; Hess DM; Jusko WJ
    J Pharmacol Exp Ther; 1998 Aug; 286(2):925-30. PubMed ID: 9694951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor.
    Wong H; Vernillet L; Peterson A; Ware JA; Lee L; Martini JF; Yu P; Li C; Del Rosario G; Choo EF; Hoeflich KP; Shi Y; Aftab BT; Aoyama R; Lam ST; Belvin M; Prescott J
    Clin Cancer Res; 2012 Jun; 18(11):3090-9. PubMed ID: 22496205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical pharmacokinetics of MHAA4549A, a human monoclonal antibody to influenza A virus, and the prediction of its efficacious clinical dose for the treatment of patients hospitalized with influenza A.
    Gupta P; Kamath AV; Park S; Chiu H; Lutman J; Maia M; Tan MW; Xu M; Swem L; Deng R
    MAbs; 2016 Jul; 8(5):991-7. PubMed ID: 27031797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of humanized monoclonal anti-IL-13 antibodies with different IL-13 neutralization mechanisms.
    Vugmeyster Y; Szklut P; Tchistiakova L; Abraham W; Kasaian M; Xu X
    Int Immunopharmacol; 2008 Mar; 8(3):477-83. PubMed ID: 18279802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis.
    Betts AM; Clark TH; Yang J; Treadway JL; Li M; Giovanelli MA; Abdiche Y; Stone DM; Paralkar VM
    J Pharmacol Exp Ther; 2010 Apr; 333(1):2-13. PubMed ID: 20089807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical disposition of GDC-0973 and prospective and retrospective analysis of human dose and efficacy predictions.
    Choo EF; Belvin M; Boggs J; Deng Y; Hoeflich KP; Ly J; Merchant M; Orr C; Plise E; Robarge K; Martini JF; Kassees R; Aoyama RG; Ramaiya A; Johnston SH
    Drug Metab Dispos; 2012 May; 40(5):919-27. PubMed ID: 22315332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies.
    Camidge DR; Herbst RS; Gordon MS; Eckhardt SG; Kurzrock R; Durbin B; Ing J; Tohnya TM; Sager J; Ashkenazi A; Bray G; Mendelson D
    Clin Cancer Res; 2010 Feb; 16(4):1256-63. PubMed ID: 20145186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2.
    Motoki K; Mori E; Matsumoto A; Thomas M; Tomura T; Humphreys R; Albert V; Muto M; Yoshida H; Aoki M; Tamada T; Kuroki R; Yoshida H; Ishida I; Ware CF; Kataoka S
    Clin Cancer Res; 2005 Apr; 11(8):3126-35. PubMed ID: 15837769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach.
    Betts A; Keunecke A; van Steeg TJ; van der Graaf PH; Avery LB; Jones H; Berkhout J
    MAbs; 2018 Jul; 10(5):751-764. PubMed ID: 29634430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and pharmacodynamics of a humanized monoclonal antibody to factor IX in cynomolgus monkeys.
    Benincosa LJ; Chow FS; Tobia LP; Kwok DC; Davis CB; Jusko WJ
    J Pharmacol Exp Ther; 2000 Feb; 292(2):810-6. PubMed ID: 10640322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.